DIAMEDICA
DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The only universally approved stroke treatment is tissue plasminogen activator (tPA) which can only be administered to patients within 4.5 hours of acute ischemic stroke. However, a urine-derived form of human tissue kallikrein-1 (uKLK1) has been approved in China for up to 48 hours post-stroke by promoting cerebral vascular circu... lation, angiogenesis and inhibiting apoptosis. Published clinical studies have found uKLK1 is also effective in combination with tPA in stroke patients. DiaMedica’s DM199 has been administered to close to 100 patients and demonstrated a safe and well tolerated profile. The Company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. The Company is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases.
DIAMEDICA
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2000-01-01
Address:
Minneapolis, Minnesota, United States
Country:
United States
Website Url:
http://www.diamedica.com
Total Employee:
1+
Status:
Active
Contact:
(763)270-0603
Email Addresses:
[email protected]
Total Funding:
87.19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-06-30 | Sanomune | Sanomune acquired by DiaMedica | N/A |
Investors List
SK Group
SK Group investment in Post-IPO Equity - DiaMedica
Fosun Pharma
Fosun Pharma investment in Post-IPO Equity - DiaMedica
Hermed Capital
Hermed Capital investment in Post-IPO Equity - DiaMedica
Genesys Venture
Genesys Venture investment in Pre Seed Round - DiaMedica
Key Employee Changes
Official Site Inspections
http://www.diamedica.com Semrush global rank: 2.72 M Semrush visits lastest month: 6.03 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "DiaMedica"
About DiaMedica :: DiaMedica Therapeutics, Inc. (DMAC)
DiaMedica Therapeutics Provides a Business Update and …
Nov 13, 2024 DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a …See details»
DiaMedica Therapeutics Announces Formation of Scientific …
4 days ago MINNEAPOLIS, December 03, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments …See details»
DiaMedica - Crunchbase Company Profile & Funding
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available. The company's treatments primarily focus on on chronic kidney …See details»
DiaMedica Therapeutics Provides a Business Update and …
MINNEAPOLIS, November 13, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe …See details»
DiaMedica Therapeutics Provides a Business Update and …
Nov 13, 2023 DiaMedica has been working closely with PPD Development, L.P., its contract research organization (CRO), on the re-initiation of the study in parallel to the FDA protocol …See details»
DiaMedica Therapeutics Inc. | LinkedIn
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are ...See details»
DiaMedica Therapeutics Inc. (DMAC) - Stock Analysis
Nov 27, 2024 DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute …See details»
Investor Relations :: DiaMedica Therapeutics, Inc. (DMAC)
Oct 9, 2024 DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.See details»
DiaMedica - Funding, Financials, Valuation & Investors - Crunchbase
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. ... How much …See details»
DiaMedica Therapeutics Announces Formation of Scientific …
5 days ago DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a …See details»
DiaMedica Therapeutics Provides a Business Update and ... - Nasdaq
Nov 13, 2023 DiaMedica has been working closely with PPD Development, L.P., its contract research organization (CRO), on the re-initiation of the study in parallel to the FDA protocol …See details»
DiaMedica Therapeutics - Overview, News & Similar companies
May 30, 2024 DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 MINNEAPOLIS--(BUSINESS WIRE)- …See details»
DiaMedica Therapeutics Announces Formation of Scientific …
4 days ago DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to …See details»
Board of Directors :: DiaMedica Therapeutics, Inc. (DMAC)
Mr. Pilnik has served as the President and member of the board of directors of Vigor Medical Services, Inc. since 2017. From 2015 to 2017, Mr. Pilnik served as a member of the board of …See details»
DiaMedica Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
DiaMedica Therapeutics Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Three …See details»
Press Releases :: DiaMedica Therapeutics, Inc. (DMAC)
Nov 12, 2024 DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 . Oct 09, 2024 8:27am EDT. DiaMedica …See details»
DiaMedica Therapeutics Announces Formation of Scientific
4 days ago DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to announce the …See details»
DiaMedica Therapeutics to Report Third Quarter 2023 Financial …
Nov 6, 2023 DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on …See details»